Page 11 - Read Online

replicative adenovirus AdDelta24‑p53 against human malignant 26. Jiang H, White EJ, Ríos‑Vicil CI, Xu J, Gomez‑Manzano C, Fueyo J.
glioma. Cancer Res 2004;64:5753‑9. Human adenovirus type 5 induces cell lysis through autophagy and
19. Li X, Mao Q, Wang D, Zhang W, Xia H. A fiber chimeric CRAd vector autophagy‑triggered caspase activity. J Virol 2011;85:4720‑9.
Ad5/11‑D24 double‑armed with TRAIL and arresten for enhanced 27. Chinnery F, King CA, Elliott T, Bateman AR, James E. Viral antigen
glioblastoma therapy. Hum Gene Ther 2012;23:589‑96. mediated NKp46 activation of NK cells results in tumor rejection via
20. Conrad C, Miller CR, Ji Y, Gomez‑Manzano C, Bharara S, NK‑DC crosstalk. Oncoimmunology 2012;1:874‑83.
McMurray JS, Lang FF, Wong F, Sawaya R, Yung WK, Fueyo J. 28. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol
Delta24‑hyCD adenovirus suppresses glioma growth in vivo by 2012;30:658‑70.
combining oncolysis and chemosensitization. Cancer Gene Ther 29. Jiang H, Clise‑Dwyer K, Ruisaard KE, Fan X, Tian W,
2005;12:284‑94. Gumin J, Lamfers ML, Kleijn A, Lang FF, Yung WK, Vence LM,
21. Lamfers ML, Gianni D, Tung CH, Idema S, Schagen FH, Gomez‑Manzano C, Fueyo J. Delta‑24‑RGD oncolytic adenovirus
Carette JE, Quax PH, Van Beusechem VW, Vandertop WP, elicits anti‑glioma immunity in an immunocompetent mouse model.
Dirven CM, Chiocca EA, Gerritsen WR. Tissue inhibitor of PLoS One 2014;9:e97407.
metalloproteinase‑3 expression from an oncolytic adenovirus inhibits 30. Pesonen S, Diaconu I, Cerullo V, Escutenaire S, Raki M,
matrix metalloproteinase activity in vivo without affecting antitumor Kangasniemi L, Nokisalmi P, Dotti G, Guse K, Laasonen L,
efficacy in malignant glioma. Cancer Res 2005;65:9398‑405. Partanen K, Karli E, Haavisto E, Oksanen M, Karioja‑Kallio A,
22. Mitlianga PG, Sioka C, Vartholomatos G, Goussia A, Polyzoidis K, Hannuksela P, Holm SL, Kauppinen S, Joensuu T, Kanerva A,
Rao JS, Kyritsis AP. p53 enhances the Delta‑24 conditionally Hemminki A. Integrin targeted oncolytic adenoviruses Ad5‑D24‑RGD
replicative adenovirus anti‑glioma effect. Oncol Rep 2006;15:149‑53. and Ad5‑RGD‑D24‑GMCSF for treatment of patients with
23. Alonso MM, Gomez‑Manzano C, Jiang H, Bekele NB, Piao Y, advanced chemotherapy refractory solid tumors. Int J Cancer
Yung WK, Alemany R, Fueyo J. Combination of the oncolytic 2012;130:1937‑47.
adenovirus ICOVIR‑5 with chemotherapy provides enhanced 31. Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Cremer I, Erbs P,
anti‑glioma effect in vivo. Cancer Gene Ther 2007;14:756‑61. Limacher JM, Preville X, Zitvogel L, Kroemer G, Galluzzi L. Trial
24. Idema S, Lamfers ML, van Beusechem VW, Noske DP, Heukelom S, Watch: oncolytic viruses for cancer therapy. Oncoimmunology
Moeniralm S, Gerritsen WR, Vandertop WP, Dirven CM. AdDelta24 2014;3:e28694.
and the p53‑expressing variant AdDelta24‑p53 achieve potent
anti‑tumor activity in glioma when combined with radiotherapy.
J Gene Med 2007;9:1046‑56. Cite this article as: Tsamis KI, Alexiou GA, Kyritsis AP. Targeting glioblastoma
25. Gomez‑Manzano C, Alonso MM, Yung WK, McCormick F, Curiel DT, with oncolytic adenovirus delta 24. Neuroimmunol Neuroinflammation
2015;2(1):1-3.
Lang FF, Jiang H, Bekele BN, Zhou X, Alemany R, Fueyo J. Delta‑24
increases the expression and activity of topoisomerase I and enhances Source of Support: Nil. Conflict of Interest: No.
the antiglioma effect of irinotecan. Clin Cancer Res 2006;12:556‑62. Received: 28-08-2014; Accepted: 26-09-2014

Neuroimmunol Neuroinflammation | Volume 2 | Issue 1 | January 15, 2015 3